More on Corcept Therapeutics (CORT): Q4 is largely in-line on EPS, but a bit shy on the revenue...

|About: Corcept Therapeutics Incorp... (CORT)|By:, SA News Editor

More on Corcept Therapeutics (CORT): Q4 is largely in-line on EPS, but a bit shy on the revenue side. Net profit declined Y/Y, as the drug developer racked up higher SG&A expenses due to increased staffing, consultancy and other professional services costs related to the rollout of Korlym.